ES2019728A6 - Procedimiento de preparacion de una vacuna de inmunoterapia para tumores de melanoma. - Google Patents

Procedimiento de preparacion de una vacuna de inmunoterapia para tumores de melanoma.

Info

Publication number: ES2019728A6
Authority: ES; Spain
Prior art keywords: cell; vaccine; produced; antigens; msm
Prior art date: 1988-09-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES8903606A

Other languages

English (en)

Spanish (es)

Inventor

Malcolm S Mitchell

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Southern California USC

Original Assignee

University of Southern California USC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-09-23

Filing date

1989-09-22

Publication date

1991-07-01

1989-09-22 Application filed by University of Southern California USC filed Critical University of Southern California USC

1991-07-01 Publication of ES2019728A6 publication Critical patent/ES2019728A6/es

2009-09-22 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

206010028980 Neoplasm Diseases 0.000 title abstract 4
201000001441 melanoma Diseases 0.000 title abstract 4
229940032219 immunotherapy vaccine Drugs 0.000 title abstract 2
239000000427 antigen Substances 0.000 abstract 3
102000036639 antigens Human genes 0.000 abstract 3
108091007433 antigens Proteins 0.000 abstract 3
239000013592 cell lysate Substances 0.000 abstract 3
229960005486 vaccine Drugs 0.000 abstract 3
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
239000002671 adjuvant Substances 0.000 abstract 2
210000004027 cell Anatomy 0.000 abstract 2
229960001438 immunostimulant agent Drugs 0.000 abstract 2
239000003022 immunostimulating agent Substances 0.000 abstract 2
230000003308 immunostimulating effect Effects 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
231100000252 nontoxic Toxicity 0.000 abstract 2
230000003000 nontoxic effect Effects 0.000 abstract 2
108010039939 Cell Wall Skeleton Proteins 0.000 abstract 1
230000000735 allogeneic effect Effects 0.000 abstract 1
238000004113 cell culture Methods 0.000 abstract 1
210000004520 cell wall skeleton Anatomy 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
239000002158 endotoxin Substances 0.000 abstract 1
244000005700 microbiome Species 0.000 abstract 1
229940035032 monophosphoryl lipid a Drugs 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 abstract 1
210000004881 tumor cell Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

ES8903606A 1988-09-23 1989-09-22 Procedimiento de preparacion de una vacuna de inmunoterapia para tumores de melanoma. Expired - Lifetime ES2019728A6 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US24854388A	1988-09-23	1988-09-23

Publications (1)

Publication Number	Publication Date
ES2019728A6 true ES2019728A6 (es)	1991-07-01

Family

ID=22939592

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES8903606A Expired - Lifetime ES2019728A6 (es)	1988-09-23	1989-09-22	Procedimiento de preparacion de una vacuna de inmunoterapia para tumores de melanoma.

Country Status (4)

Country	Link
JP (1)	JPH04501663A (fr)
AU (1)	AU4338189A (fr)
ES (1)	ES2019728A6 (fr)
WO (1)	WO1990003183A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9620350D0 (en)	1996-09-30	1996-11-13	Maudsley David J	Cancer vaccine
DE60040213D1 (de)	1999-02-09	2008-10-23	Riken Wako	Tumorimpfstoff
WO2000071156A2 (fr) *	1999-05-21	2000-11-30	Onyvax Limited	Nouvelles formulations vaccinales-3
US8409564B2 (en)	1999-10-05	2013-04-02	Universite De Montreal	Rhodamine derivatives for photodynamic diagnosis and treatment
RU2152800C1 (ru) *	1999-12-08	2000-07-20	Зыбин Дмитрий Владимирович	Способ культивирования и модификации гетерогенных клеток млекопитающих
RU2192884C2 (ru) *	2000-11-09	2002-11-20	Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН	Вакцина для стимуляции противоопухолевого иммунитета
WO2003028758A1 (fr) *	2001-09-28	2003-04-10	Haruo Sugiyama	Nouvelle methode d'induction de lymphocytes t specifiques d'un antigene
US7176022B2 (en)	2002-12-20	2007-02-13	Cell Genesys, Inc.	Directly injectable formulations which provide enhanced cryoprotection of cell products
MXPA06006286A (es) *	2003-12-05	2006-09-04	Univ Montreal	Compuestos inmunologicos para prevencion, proteccion, profilaxis o tratamiento de trastornos inmunologicos, infecciones y cancer.
GB0601598D0 (en) *	2006-01-26	2006-03-08	Stathopoulos Apostolos	Method
RU2392316C1 (ru) *	2008-12-26	2010-06-20	Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН	КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Ksen, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2012156969A1 (fr)	2011-05-17	2012-11-22	Hadasit Medical Research Services And Development Ltd.	Vaccination par des cellules tumorales allogéniques
PL2941233T3 (pl) *	2013-01-07	2021-03-08	The Trustees Of The University Of Pennsylvania	Kompozycje i sposoby leczenia chłoniaka z komórek t typu pierwotnie skórnego

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4436727A (en) *	1982-05-26	1984-03-13	Ribi Immunochem Research, Inc.	Refined detoxified endotoxin product
US4505900A (en) *	1982-05-26	1985-03-19	Ribi Immunochem Research, Inc.	Refined detoxified endotoxin product
US4806352A (en) *	1986-04-15	1989-02-21	Ribi Immunochem Research Inc.	Immunological lipid emulsion adjuvant
US4877611A (en) *	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants

1989
- 1989-09-22 WO PCT/US1989/004139 patent/WO1990003183A1/fr not_active Ceased
- 1989-09-22 AU AU43381/89A patent/AU4338189A/en not_active Abandoned
- 1989-09-22 ES ES8903606A patent/ES2019728A6/es not_active Expired - Lifetime
- 1989-09-22 JP JP1510450A patent/JPH04501663A/ja active Pending

Also Published As

Publication number	Publication date
WO1990003183A1 (fr)	1990-04-05
JPH04501663A (ja)	1992-03-26
AU4338189A (en)	1990-04-18

Similar Documents

Publication	Publication Date	Title
ES2019728A6 (es)	1991-07-01	Procedimiento de preparacion de una vacuna de inmunoterapia para tumores de melanoma.
UA40597C2 (uk)	2001-08-15	Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
TR200100936T2 (tr)	2001-08-21	Terapötik aşılama
Hanna Jr et al.	1972	Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. II. Comparative effects of vaccinia virus, oxazolone, and turpentine
PL325964A1 (en)	1998-08-17	Dendritic cells stimulating factor
EP0752870B1 (fr)	2002-06-05	Utilisation de mycobacterium pour le traitement des tumeurs
MXPA03003638A (es)	2004-01-26	Inmunoterapia con vacuna para pacientes inmunosuprimidos.
CN101282742A (zh)	2008-10-08	脂质体在含连续疏水相的载体中作为癌症治疗媒介物的应用
WO1998033527A3 (fr)	1998-11-05	Immunotherapie anticancer a base de cellules semi-allogeniques
Ollila et al.	1998	Overview of melanoma vaccines: active specific immunotherapy for melanoma patients
MXPA04003864A (es)	2004-08-11	Inmunoterapia para revertir la supresion inmune.
AR068984A1 (es)	2009-12-23	Proceso para la obtencion de celulas presentadoras de antigenos activados, utiles en las terapias contra el cancer y enfermedades relacionadas del sistema inmunologico
Eilber et al.	1971	Immunotherapy experiments with a methylcholanthrene-induced guinea pig liposarcoma
AU7767000A (en)	2001-04-23	Archaeosomes as immunomodulating carriers for acellular vaccines to induce cytotoxic t lymphocyte (ctl) responses and protect the vaccinated host against intracellular pathogens and cancer
Conforti et al.	1997	Update on active specific immunotherapy with melanoma vaccines
NZ507829A (en)	2004-03-26	Vaccine adjuvants for immunotherapy of melanoma
Decrausaz et al.	2011	Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus‐associated genital tumors
Conacher et al.	2000	Niosomes as immunological adjuvants
CA2330313A1 (fr)	1999-11-11	Immunisation et traitement anti-infectieux
Likhite	1974	The delayed and lasting rejection of mammary adenocarcinoma cell tumors in DBA/2 mice with use of killed Bordetella pertussis
US6090385A (en)	2000-07-18	Method of treating cancer
Douin-Echinard et al.	1998	Enhancement of anti-tumor immunity by injection of fibroblasts genetically engineered to produce IL-12 and to express CD70
WO1995032286A3 (fr)	1995-12-28	Antigene immunogene carcinoembryonnaire et procedes d'utilisation et de production de cet antigene
US6056964A (en)	2000-05-02	Immunotherapeutic agent and its use
Weiner	2000	Immunostimulatory DNA sequences and cancer therapy

Legal Events

Date	Code	Title	Description
1992-01-01	SA6	Expiration date (snapshot 920101)	Free format text: 2009-09-22